The Canadian Intellectual Property Office intends to grant RhoVac’s patent application for RV001 (onilcamotide) cancer vaccine
RhoVac AB (”RhoVac”) announces today, 24[th] January 2022, that the Canadian Intellectual Property Office (”CIPO”) has issued a “Notice of Allowance”, which means that it intends to grant RhoVac’s patent application for RV001 (onilcamotide) cancer vaccine. The company has previously been granted patents relating to onilcamotide in USA, Europe and Japan. The Canadian patent will provide RhoVac’s onilcamotide vaccine with broad protection in a key market and significantly strengthens the company’s patent portfolio.The Canadian Intellectual Property Office (”CIPO”) has communicated its